{
    "paper_id": "PMC7152179",
    "metadata": {
        "title": "Pneumopathies infectieuses communautaires",
        "authors": [
            {
                "first": "Dominique",
                "middle": [],
                "last": "Pateron",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Maurice",
                "middle": [],
                "last": "Rapha\u00ebl",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Albert",
                "middle": [],
                "last": "Trinh-Duc",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Infection aigu\u00eb du parenchyme pulmonaire survenue en ambulatoire ou dans les 48 h du d\u00e9but de l'hospitalisation.",
            "cite_spans": [],
            "section": "D\u00e9finition",
            "ref_spans": []
        },
        {
            "text": "Insuffisance respiratoire chronique, n\u00e9oplasie, tabagisme ou alcoolisme chronique.",
            "cite_spans": [],
            "section": "Ant\u00e9c\u00e9dents ::: Anamn\u00e8se\u00a0: d\u00e9faillance immunitaire ou exposition ::: D\u00e9marche diagnostique ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "M\u00e9tiers, animaux, corticoth\u00e9rapie, voyages r\u00e9cents.",
            "cite_spans": [],
            "section": "Exposition ::: Anamn\u00e8se\u00a0: d\u00e9faillance immunitaire ou exposition ::: D\u00e9marche diagnostique ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\nTableau14.1\n, performance des diff\u00e9rents \u00e9l\u00e9ments cliniques [1].",
            "cite_spans": [
                {
                    "start": 62,
                    "end": 63,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Examen clinique ::: D\u00e9marche diagnostique ::: Diagnostic",
            "ref_spans": [
                {
                    "start": 1,
                    "end": 12,
                    "mention": "Tableau14.1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "\n\u2022Polynucl\u00e9ose ou inversement leucop\u00e9nie (associ\u00e9e \u00e0 une surmortalit\u00e9 et un risque de syndrome de d\u00e9faillance respiratoire aigu\u00eb [SDRA]).\u2022Thrombop\u00e9nie : facteur de mauvais pronostic.\n",
            "cite_spans": [],
            "section": "NFS ::: Examens biologiques ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Identification du germe que dans 6 % des cas.\u2022Pr\u00e9disposition de bact\u00e9ri\u00e9mie positive lors de suspicion d'endocardite, de T\u00b0 > \n 39,4 \u00b0C ou chez les patients porteurs de cath\u00e9ters veineux ainsi qu'en pr\u00e9sence de facteurs consid\u00e9r\u00e9s comme mineurs (SIRS, \u00e2ge, insuffisance r\u00e9nale, frissons) [2].\u2022Pas d'indication pour les PAC non grave et sans facteur de risque.\u2022Rentabilit\u00e9 de cet examen corr\u00e9l\u00e9e au volume de sang pr\u00e9lev\u00e9 (20 mL). Une h\u00e9moculture suffit dans la plupart des cas.\n",
            "cite_spans": [
                {
                    "start": 291,
                    "end": 292,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "H\u00e9mocultures ::: Examens biologiques ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Taux : pas de bonne sensibilit\u00e9 ni de bonne sp\u00e9cificit\u00e9 pour pr\u00e9ciser le diagnostic microbiologique de PAC.\u2022Pas sa place dans la PAC sans gravit\u00e9 chez des patients sans facteur de comorbidit\u00e9.\u2022> \n 48 mg/mL, peut aider \u00e0 diff\u00e9rencier une PAC \u00e0 une exacerbation de BPCO ou d'asthme.\n",
            "cite_spans": [],
            "section": "CRP ::: Examens biologiques ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Marqueur plus sensible et plus sp\u00e9cifique d'une infection bact\u00e9rienne.\u2022Jamais interpr\u00e9t\u00e9e seul, permet d'am\u00e9liorer la probabilit\u00e9 post-test.\u2022Devant probabilit\u00e9 pr\u00e9test \u00e9lev\u00e9e et seuil < \n 0,1 \u03bcg/L (qui autoriserait une abstention d'antibiotique) contr\u00f4le \u00e0 12 h.\u2022Seuil de > \n 0,25 \u03bcg/L semble acceptable pour initier une antibioth\u00e9rapie.\u2022Ce biomarqueur est actuellement remis en cause dans cette indication [3].\n",
            "cite_spans": [
                {
                    "start": 410,
                    "end": 411,
                    "mention": "3",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "PCT ::: Examens biologiques ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022R\u00e9sultat en 15 min.\u2022Uniquement pour les PAC s\u00e9v\u00e8res.\u2022D\u00e9tectables m\u00eame si patient sous antibioth\u00e9rapie et persistance de nombreuses semaines (Legionella).\u2022\nStreptococcus pneumoni\u00e6\n : Streptococcus pneumoni\u00e6sensibilit\u00e9 (Se) de 50 \u00e0 80 % et sp\u00e9cificit\u00e9 (Sp) > \n 90 %.\u2022\nLegionella pneumophila s\u00e9rogroupeLegionella pneumophila 1 : Se : 70 \u00e0 100 %, Sp : > \n 99 %.\n",
            "cite_spans": [],
            "section": "Antig\u00e8nes solubles urinaires ::: Examens biologiques ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Lors d'\u00e9pid\u00e9mie de grippe, permet d'affirmer le diagnostic mais pas de l'\u00e9liminer.\u2022Conditions de pr\u00e9l\u00e8vements essentielles.\n",
            "cite_spans": [],
            "section": "Immunochromatographie sur s\u00e9cr\u00e9tions nasopharyng\u00e9es (test\u00a0de d\u00e9pistage rapide) ::: Examens biologiques ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "La radiographie du thorax : l'examen de r\u00e9f\u00e9rence.\u2022Opacit\u00e9 parenchymateuse alv\u00e9olaire avec bronchogramme a\u00e9rien prenant un aspect syst\u00e9matis\u00e9 lobaire.\u2022Cavit\u00e9s, \u00e9panchement pleural ou images interstitielles.\u2022L'\u00e9chographie au lit du malade peut aider au diagnostic, mais les \u00e9tudes montrent une grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 (Sp 57 \u00e0 100 % Sp 54 \u00e0 100 %) [4].\n",
            "cite_spans": [
                {
                    "start": 345,
                    "end": 346,
                    "mention": "4",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "Imagerie ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Insuffisance cardiaque aigu\u00eb associ\u00e9e une pathologie virale.\u2022Pneumopathie d'inhalation.\u2022Embolie pulmonaire.\u2022Exacerbation de bronchectasie ou de fibrose pulmonaire.\n",
            "cite_spans": [],
            "section": "Avec radiographie du thorax anormale ::: Diagnostic diff\u00e9rentiel ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Exacerbation BPCO.\u2022Grippe.Grippe\n\u2022BronchiteBronchite aigu\u00eb aigu\u00eb.\u2022Asthme avec virose.\n",
            "cite_spans": [],
            "section": "Avec radiographie du thorax normale ::: Diagnostic diff\u00e9rentiel ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022\nStreptococcus pneumoni\u00e6\nStreptococcus pneumoni\u00e6(27 %).\u2022Germes atypiques (25 %) :\u2013\nMycoplasma pneumoni\u00e6\nMycoplasma pneumoni\u00e6(12 %) ;\u2013\nChlamydia pneumoni\u00e6\nChlamydia pneumoni\u00e6(7 %) ;\u2013\nLegionella pneumophila\nLegionella pneumophila(5 %).\n\u2022Bacille Gram n\u00e9gatif (11 %). Facteurs favorisants inhalation, comorbidit\u00e9s, antibioth\u00e9rapie ant\u00e9rieure ou hospitalisation r\u00e9cente.\n",
            "cite_spans": [],
            "section": "Bact\u00e9ries ::: \u00c9tiologie ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022\nInfluenzavirus\nInfluenzavirus(10 %).\u2022RhinovirusRhinovirus (10 %).\u2022VRSVirus respiratoire syncytial, Ad\u00e9novirusad\u00e9novirus, Coronaviruscoronavirus (8 %).\n",
            "cite_spans": [],
            "section": "Virus (20\u00a0%) ::: \u00c9tiologie ::: Diagnostic",
            "ref_spans": []
        },
        {
            "text": "Objet de nombreuses publications, scores de mortalit\u00e9 sp\u00e9cifiques aux PAC ; uniquement une aide sans se substituer \u00e0 une \u00e9valuation individualis\u00e9e du patient :\u2022le Scorede Finescore de Fine (tableau14.3\n) : le plus valid\u00e9 ;\u2022le ScoreCURB65score CURB65 (tableau14.4\n) : le plus facilement applicable.\n",
            "cite_spans": [],
            "section": "Gravit\u00e9 ::: \u00c9l\u00e9ments de gravit\u00e9 et pronostic",
            "ref_spans": [
                {
                    "start": 190,
                    "end": 201,
                    "mention": "tableau14.3",
                    "ref_id": "TABREF2"
                },
                {
                    "start": 251,
                    "end": 262,
                    "mention": "tableau14.4",
                    "ref_id": "TABREF6"
                }
            ]
        },
        {
            "text": "Retenus par les soci\u00e9t\u00e9s savantes mais jamais valid\u00e9s dans des \u00e9tudes prospectives :\u2022Fr\u00e9quence respiratoire > \n 30 cycles/min ;\u2022Insuffisance respiratoire s\u00e9v\u00e8re (PaO2/FiO2 < \n 250) ou n\u00e9cessit\u00e9 de ventilation m\u00e9canique ;\u2022Images bilat\u00e9rales ou atteinte de plus de 2 lobes \u00e0 la radiographie thoracique ;\u2022PAS \u2264 \n 90 mmHg ou PAD \u2264 \n 60 mmHg, n\u00e9cessit\u00e9 de dose vasoactive pendant plus de 4 h ;\u2022Diur\u00e8se < \n 20 mL/h ou < \n 80 mL/4 h ou indication d'\u00e9puration extrar\u00e9nale.\n",
            "cite_spans": [],
            "section": "Crit\u00e8res d'admission en r\u00e9animation ::: \u00c9l\u00e9ments de gravit\u00e9 et pronostic",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Mortalit\u00e9 \u00e0 30 jours varie en fonction du niveau de gravit\u00e9, en moyenne de 5 \u00e0 10 %.\u2022Retard dans l'initiation de l'antibioth\u00e9rapie : impact sur la mortalit\u00e9 chez les patients > \n 65 ans.\u202210 % des PAC vues aux urgences n\u00e9cessiteront la r\u00e9animation.\n",
            "cite_spans": [],
            "section": "Pronostic ::: \u00c9l\u00e9ments de gravit\u00e9 et pronostic",
            "ref_spans": []
        },
        {
            "text": "\n\n\u2013Dans les 4 h qui suivent le diagnostic.\u2013Streptococcus pneumoni\u00e6 prioritairementStreptococcus pneumoni\u00e6 et syst\u00e9matiquement pris en compte.\u2013AmoxicillineAmoxicilline antibiotique de premi\u00e8re intention des PAC non graves [6].\u2013Choix de l'antibiotique et voie d'administration d\u00e9pendent de la gravit\u00e9 de la maladie et du terrain (tableaux14.5 et \n14.6\n).\u2013Le tableau14.7\nles diff\u00e9rents sch\u00e9mas posologiques en fonction des antibiotiques recommand\u00e9s.\u2013R\u00e9\u00e9valuation de l'efficacit\u00e9 est obligatoire dans les 48\u201372 h.\u2013Voie orale doit \u00eatre privil\u00e9gi\u00e9e.\u2013La dur\u00e9e d'antibioth\u00e9rapie ne peut pas \u00eatre guid\u00e9e par un biomarqueur [5, 7].\n\n",
            "cite_spans": [
                {
                    "start": 222,
                    "end": 223,
                    "mention": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 615,
                    "end": 616,
                    "mention": "5",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 618,
                    "end": 619,
                    "mention": "7",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "Antibiotique\u00a0[5bb0030bibr] Image 13 ::: Prise en charge th\u00e9rapeutique",
            "ref_spans": [
                {
                    "start": 328,
                    "end": 340,
                    "mention": "tableaux14.5",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 345,
                    "end": 349,
                    "mention": "14.6",
                    "ref_id": "TABREF4"
                },
                {
                    "start": 356,
                    "end": 367,
                    "mention": "tableau14.7",
                    "ref_id": "TABREF5"
                }
            ]
        },
        {
            "text": "\n\u2022R\u00e9server aux PAC graves [8].\u2022R\u00e9duisent la dur\u00e9e de l'oxyg\u00e9noth\u00e9rapie et la n\u00e9cessit\u00e9 de ventilation m\u00e9canique mais ne modifient pas la mortalit\u00e9 (niveau de preuve faible).\u2022Posologie de 1 mg/kg de prednisolone pendant 7 jours semble suffisant [9].\n",
            "cite_spans": [
                {
                    "start": 27,
                    "end": 28,
                    "mention": "8",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 245,
                    "end": 246,
                    "mention": "9",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Cortico\u00efdes ::: Prise en charge th\u00e9rapeutique",
            "ref_spans": []
        },
        {
            "text": "\n\u2022\u00ab \n Bon sens \u00bb clinique du praticien tient compte de la nature des facteurs de risque et doit \u00eatre d\u00e9terminant, notamment en cas d'immunod\u00e9pression.\u2022Scores pr\u00e9dictifs de mortalit\u00e9 non \u00e9valu\u00e9s pour \u00eatre des outils de d\u00e9cision d'hospitalisation.\u2022Habituellement CRB65CRB65 \u00e0 0 [5] ou Score de Finescore de Fine \u2264 \n III [1], autorisent un traitement ambulatoire.\u2022Consultation m\u00e9dicale de r\u00e9\u00e9valuation dans les 48 h \u00e0 programmer.\n",
            "cite_spans": [
                {
                    "start": 277,
                    "end": 278,
                    "mention": "5",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 319,
                    "end": 320,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Surveillance et consignes (#!start#figure14.1#!sep#f0010#!sep#fig#!end#)\u00a0[#!start#5#!sep#bb0030#!sep#bibr#!end#]",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Tableau 14.1: Valeurs diagnostiques des diff\u00e9rents \u00e9l\u00e9ments cliniques, biologiques, radiologiques pour le diagnostic de PNPC [1].\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Tableau\u00a014.2: \u00c9l\u00e9ments d'orientation diagnostique des PAC.\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Tableau\u00a014.3: \u00c9valuation du risque de mortalit\u00e9 \u00e0 30 jours des patients atteints d'une PNPC : score de Fine ou PSI.\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Tableau\u00a014.5: Antibioth\u00e9rapie probabiliste des PAC non graves aux urgences [5](1)Image 2.\n",
            "type": "table"
        },
        "TABREF4": {
            "text": "Tableau\u00a014.6: MucoviscidoseImip\u00e9n\u00e8meM\u00e9rop\u00e9n\u00e8mePip\u00e9racilline/tazobactamC\u00e9f\u00e9pimeCarbap\u00e9n\u00e8meDorip\u00e9n\u00e8meAntibioth\u00e9rapie probabiliste des PAC Image 4graves aux soins intensifs ou en r\u00e9animation [5](1).\n",
            "type": "table"
        },
        "TABREF5": {
            "text": "Tableau\u00a014.7: AmoxicillineAmoxicilline/acide clavulaniqueOxacillineCeftriaxoneC\u00e9fotaximePip\u00e9racilline/tazobactamC\u00e9f\u00e9pimeImip\u00e9n\u00e8me/cilastatineM\u00e9rop\u00e9n\u00e8meDorip\u00e9n\u00e8me\u00c9rythromycineClarithromycineJosamycineRoxithromycineSpiramycinePristinamycineT\u00e9lithromycineL\u00e9vofloxacineMoxifloxacineAmikacineSch\u00e9mas d'administration pr\u00e9conis\u00e9s pour les antibiotiques recommand\u00e9s dans\u00c9rythromycine la prise en charge des pneumonies aigu\u00ebs communautaires (posologies quotidiennes \u00e9tablies pour un adulte \u00e0 la fonction r\u00e9nale normale) [5](1).\n",
            "type": "table"
        },
        "TABREF6": {
            "text": "Tableau\u00a014.4: \u00c9valuation du risque de mortalit\u00e9 \u00e0 30 jours des patients atteints d'une PNPC : score CURB65 Image 1.\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 14.1: Algorithme de prise en charge d'une pneumopathie aigu\u00eb communautaire [1].",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Testing strategies in the initial management of patients with community-acquired pneumonia",
            "authors": [
                {
                    "first": "J.P.",
                    "middle": [],
                    "last": "Metlay",
                    "suffix": ""
                },
                {
                    "first": "M.J.",
                    "middle": [],
                    "last": "Fine",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Ann Intern Med",
            "volume": "138",
            "issn": "2",
            "pages": "109-118",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Does this adult patient with suspected bacteremia require blood cultures\u00a0?",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Coburn",
                    "suffix": ""
                },
                {
                    "first": "A.M.",
                    "middle": [],
                    "last": "Morris",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Tomlinson",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "JAMA",
            "volume": "308",
            "issn": "5",
            "pages": "502-511",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Procalcitonin-Guided Use of Antibiotics for\u00a0Lower Respiratory Tract Infection",
            "authors": [
                {
                    "first": "D.T.",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "D.M.",
                    "middle": [],
                    "last": "Yealy",
                    "suffix": ""
                },
                {
                    "first": "M.R.",
                    "middle": [],
                    "last": "Filbin",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "N Engl J Med",
            "volume": "379",
            "issn": "3",
            "pages": "236-249",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults : systematic review and meta-analysis",
            "authors": [
                {
                    "first": "A.M.",
                    "middle": [],
                    "last": "Llamas-\u00c1lvarez",
                    "suffix": ""
                },
                {
                    "first": "E.M.",
                    "middle": [],
                    "last": "Tenza-Lozano",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Latour-P\u00e9rez",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Chest",
            "volume": "151",
            "issn": "2",
            "pages": "374-382",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Antibioth\u00e9rapie par voie g\u00e9n\u00e9rale dans les infections respiratoires basses de l'adulte",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "AFSSAPS",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "SPILF",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "SPLF",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Antibiotic treatment strategies for community-acquired pneumonia in adults",
            "authors": [
                {
                    "first": "D.F.",
                    "middle": [],
                    "last": "Postma",
                    "suffix": ""
                },
                {
                    "first": "C.H.",
                    "middle": [],
                    "last": "van Werkhoven",
                    "suffix": ""
                },
                {
                    "first": "L.J.R.",
                    "middle": [],
                    "last": "van Elden",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "N Engl J Med",
            "volume": "372",
            "issn": "14",
            "pages": "1312-1323",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Do we need biomarkers for the follow-up and shortening of antibiotic treatment duration\u00a0?",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Dianti",
                    "suffix": ""
                },
                {
                    "first": "C.M.",
                    "middle": [],
                    "last": "Luna",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Curr Opin Crit Care",
            "volume": "24",
            "issn": "5",
            "pages": "361-369",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Corticosteroids for pneumonia",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Pu",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Cochrane Database Syst Rev",
            "volume": "3",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Adjunct prednisone therapy for patients with community-acquired pneumonia : a multicentre, double-blind, randomised, placebo-controlled trial",
            "authors": [
                {
                    "first": "C.A.",
                    "middle": [],
                    "last": "Blum",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Nigro",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Briel",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet",
            "volume": "385",
            "issn": "",
            "pages": "1511-1518",
            "other_ids": {
                "DOI": []
            }
        }
    }
}